---
title: "M Stanley: CSPC PHARMA  3Q Finished Drug Sales Slightly Beat Expectations, Multiple Pipeline Catalysts Expected"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306085932.md"
description: "Morgan Stanley maintains an Overweight rating and HKD12 target price for CSPC Pharma, citing Q3 finished drug sales slightly beating expectations with a 10% YoY increase. The bank highlights multiple pipeline catalysts, including EGFR ADC data at ESMO Asia and PD-1/IL-15 updates, reinforcing its investment thesis. Adjusted net profit rose 39% YoY, driven by strong CNS and digestive drug performance, despite declines in oncology and cardiovascular segments."
datetime: "2026-11-19T08:26:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306085932.md)
  - [en](https://longbridge.com/en/news/306085932.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306085932.md)
generator: "portal-rs"
---

# M Stanley: CSPC PHARMA  3Q Finished Drug Sales Slightly Beat Expectations, Multiple Pipeline Catalysts Expected

Morgan Stanley issued a research report stating that CSPC PHARMA (01093.HK) +0.315 (+3.945%) Short selling $200.72M; Ratio 40.930% 's finished drug sales in the third quarter were slightly above expectations, while multiple pipeline catalysts in the future reinforced the bank's investment thesis. The bank maintained its Overweight rating and HKD12 TP on CSPC PHARMA (01093.HK) +0.315 (+3.945%) Short selling $200.72M; Ratio 40.930% .

Morgan Stanley noted that the company targets continued positive growth in finished drug sales by 2027. There was no price cut for NBP under the national volume-based procurement program, while Mingfule recorded an about 9% price reduction in the National Reimbursement Drug List. In total, the company has more than 10 innovative drugs. Third-quarter finished drug sales rose 10% YoY and 2.5% QoQ. Among them, central nervous system (CNS) drugs increased 32% YoY, oncology drugs fell 23%, anti-infective drugs rose 2%, cardiovascular drugs declined 15%, respiratory drugs dropped 15%, digestive drugs increased 41%, and other drugs fell 2%.

Third-quarter business development income reached RMB373 million, while business development income for the first nine months of 2026 amounted to RMB6.3 billion, including part of the upfront payments and milestone payments from AstraZeneca's long-acting peptide platform and Nectin-4 ADC. Third-quarter gross margin rose 1 ppts YoY to 67%, while the selling and administrative expense ratio for finished drug sales fell 6 ppts. The R&D ratio remained broadly stable at 31%, and adjusted net profit for the third quarter increased 39% YoY.

The bank said the next catalysts include Phase III readout data for EGFR ADC in second-line EGFR-mutated non-small cell lung cancer to be announced at ESMO Asia in early December, as well as early durability data and potential globalization updates for PD-1/IL-15 in 2027. (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 12:25.)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)

## Related News & Research

- [CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross margin](https://longbridge.com/en/news/305926514.md)
- [CSPC Starts Phase II Trial of New RSV Drug SYH2066 in China](https://longbridge.com/en/news/302701865.md)
- [CSPC Wins China Approval for First-in-Class Batoclimab Therapy in Myasthenia Gravis](https://longbridge.com/en/news/302792343.md)
- [CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China](https://longbridge.com/en/news/304626206.md)
- [Alibaba Q2 revenue rises on AI Cloud and Compute Services strength](https://longbridge.com/en/news/306100634.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**